StevenWongMD

Oncology • Santa Monica, CA

Breast Cancer, Endocrine Cancer, Genitourinary Oncology, Hematologic Oncology

Medical Oncologist/Hematologist

Join to view full profile

Dr. Wong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wong's full profile

Already have an account?

Office
2811 Wilshire Blvd
Ste 414
Santa Monica, CA 90403
Phone+1 310-552-9999

Fax+1 310-201-6685

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 2002
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1993 - 1996
David Geffen School of Medicine at UCLAClass of 1993

Certifications & Licensure

CA State Medical License 1994 - 2026
ME State Medical License 2020 - 2026
TN State Medical License 2023 - 2026
MO State Medical License 2022 - 2025
AK State Medical License 2023 - 2024
MT State Medical License 2020 - 2024
ID State Medical License 2021 - 2023
KY State Medical License 2021 - 2022
WY State Medical License 2015 - 2016
American Board of Internal Medicine Medical Oncology
Join now to see all

Publications & Presentations

PubMed

4 citations
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.
Erlinda M Gordon, Nicole L Angel, Nadezhda Omelchenko, Victoria S Chua-Alcala, Ania Moradkhani
Anticancer Research. 2023-05-01
11 citations
SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.
Erlinda Maria Gordon, Sant P Chawla, Walter Andree Tellez, Elan Younesi, Sonu Thomas
Cancers. 2023-01-31
5 citations
A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.
Marcus S Noel, Semmie Kim, Marion L Hartley, Steve Wong, Vincent J Picozzi
Cancer Medicine. 2022-11-01

Press Mentions

Biofidelity Launches Test Offering Rapid Genomic Profiling for NSCLC PatientsNovember 21st, 2024
Insys Sponsors Cancer Caregivers Education ProgramMay 25th, 2017